

Cellular Bioenergetics after Erythropoietin Therapy in Chronic Renal Failure

Ramon M. Marrades,* Juli Alonso,† Josep Roca,* Jose M. González de Suso,‡ Josep M. Campistol,* Joan A. Barberà,* Orlando Diaz,* Josep V. Torregrosa,* Joan R. Masclans,* Robert Rodríguez-Roisin,* and Peter D. Wagner§

*Servei de Pneumologia i Al·lèrgia Respiratòria, Unitat de Transplantament Renal, Hospital Clínic, Universitat de Barcelona 08036;

†Centre Diagnòstic Pedralbes, Barcelona; Centre d'Alt Rendiment, Sant Cugat del Vallés, Spain; and §Department of Medicine, Section of Physiology, University of California, San Diego. La Jolla, California 92093-0623

Abstract

After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O₂ uptake ($\dot{V}O_2$ peak) as much as expected from the rise in hemoglobin concentration ([Hb]). In a companion study, we explain this phenomenon by the concurrent effects of fall in muscle blood flow after rHuEPO and abnormal capillary O₂ conductance observed in CRF patients. The latter is likely associated with a poor muscle microcirculatory network and capillary-myofiber dissociation due to uremic myopathy. Herein, cellular bioenergetics and its relationships with muscle O₂ transport, before and after rHuEPO therapy, were examined in eight CRF patients (27 ± 7.3 [SD] yr) studied pre- and post-rHuEPO ([Hb] = 7.8 ± 0.7 vs. 11.7 ± 0.7 g \times dl⁻¹) during an incremental cycling exercise protocol. Eight healthy sedentary subjects (26 ± 3.1 yr) served as controls. We hypothesize that uremic myopathy provokes a cytosolic dysfunction but mitochondrial oxidative capacity is not abnormal. ³¹P-nuclear magnetic resonance spectra (³¹P-MRS) from the vastus medialis were obtained throughout the exercise protocol consisting of periods of 2 min exercise (at 1.67 Hz) at increasing workloads interspersed by resting periods of 2.5 min. On a different day, after an identical exercise protocol, arterial and femoral venous blood gas data were obtained together with simultaneous measurements of femoral venous blood flow (\dot{Q}_{leg}) to calculate O₂ delivery ($\dot{Q}O_{2leg}$) and O₂ uptake ($\dot{V}O_{2leg}$). Baseline resting [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9 ± 1.2 vs. 8.8 ± 1.2 , respectively), but it was significantly lower than in controls (10.9 ± 1.5) ($P = 0.01$ each). At a given submaximal or peak $\dot{V}O_{2leg}$, no effects of rHuEPO were seen on cellular bioenergetics ([PCr]/[Pi] ratio, %PCr consumption, half-time of [PCr] recovery after exercise), nor in intracellular pH (pHi). The post-rHuEPO bioenergetic status and pHi, at a given $\dot{V}O_{2leg}$, were below those observed in the control group. However, at a given pHi, no differences in ³¹P-MRS data were detected between post-rHuEPO and controls. After rHuEPO, at peak $\dot{V}O_2$, \dot{Q}_{leg} fell 20% ($P < 0.04$), limiting

the change in $\dot{Q}O_{2leg}$ to +17%, a value that did not reach statistical significance. The corresponding O₂ extraction ratio decreased from $73 \pm 4\%$ to $68 \pm 8.2\%$ ($P < 0.03$). These changes indicate that maximal O₂ flow from microcirculation to mitochondria did not increase despite the 50% increase in [Hb] and explain how peak $\dot{V}O_{2leg}$ and cellular bioenergetics (³¹P-MRS) did not change after rHuEPO. Differences in pHi, possibly due to lactate differences, between post-rHuEPO and controls appear to be a key factor in the abnormal muscle cell bioenergetics during exercise observed in CRF patients. (*J. Clin. Invest.* 1996; 97:2101–2110.) Key words: energy metabolism • exercise • muscle O₂ transport • oxygen transport • $\dot{V}O_{2max}$

Introduction

It is known that substantial increases in hemoglobin concentration ([Hb])¹ after erythropoietin (rHuEPO) therapy in patients with chronic renal failure (CRF) are not followed by corresponding gains of maximum O₂ uptake ($\dot{V}O_{2max}$) (1–9). In a previous study with CRF patients (10), O₂ supply dependency of $\dot{V}O_{2max}$ was demonstrated. This indicates that peak $\dot{V}O_2$ is not determined by mitochondrial oxidative limits. The dissociation between increase in [Hb] and the changes of $\dot{V}O_{2max}$ after rHuEPO was explained by two factors affecting O₂ transport to the cell.

First, correction of anemia with rHuEPO therapy results in elimination of the hyperdynamic cardiac status. This returns elevated muscle blood flow (\dot{Q}) to values similar to levels seen in matched control subjects during peak exercise and partially offsets the effect of the rise in arterial O₂ content on O₂ delivery. Second, O₂ conductance from muscle microcirculation to mitochondria is particularly low in CRF patients (10) and after rHuEPO therapy still remains at ~70% of that seen in control subjects. The structural basis of this abnormal O₂ transport conductance is likely microvascular rarefaction and capillary-myofiber dissociation provoked by a uremic myopathy (11–13). As a result of these changes, the ratio of muscle diffusive to perfusive conductance as defined by Piiper et al. (14–16) may either not vary (10) or even fall after rHuEPO. Since this

Address correspondence to Josep Roca, MD, Servei de Pneumologia, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain. Phone: 343-227-5540; FAX: 343-227-5455; E-mail: roca@medicina.ub.es

Received for publication 7 September 1995 and accepted in revised form 5 March 1996.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/96/05/2101/10 \$2.00

Volume 97, Number 9, May 1996, 2101–2110

1. *Abbreviations used in this paper:* CaO₂, arterial O₂ content; C_vO₂, femoral venous O₂ content; DO₂, muscle O₂ conductance from the capillary to the mitochondria; [Hb], hemoglobin concentration; MVC, maximal voluntary contraction; [PCr]/[Pi], ratio of [phosphocreatine] to [inorganic phosphate]; %PCr consumption, phosphocreatine consumption during exercise expressed as percent of phosphocreatine at rest, measured before each exercise step; pHi, intracellular pH; $\dot{Q}O_{2leg}$, one-leg O₂ delivery; rHuEPO, recombinant human erythropoietin; $\dot{V}O_2$, whole-body O₂ uptake; $\dot{V}O_{2leg}$, one-leg O₂ uptake.

ratio determines O₂ extraction by muscle, post-rHuEPO O₂ extraction would not change or may fall (17).

We hypothesize that, in addition to the muscle O₂ transport problem described above, post-rHuEPO muscle bioenergetic status at a given $\dot{V}O_2$, as reflected by [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) at rest and during exercise, % [PCr] consumption during exercise, and half-time of [PCr] recovery after exercise, is below the values observed in normal sedentary subjects. This defect in muscle cell bioenergetics may be explained by a cytosolic dysfunction provoked by uremic myopathy. Since evidence of normal mitochondrial oxidative capacity in CRF patients has been reported (11,18), and the companion study showed that $\dot{V}O_2$ peak is O₂ supply dependent in these rHuEPO treated patients, changes in muscle bioenergetics at maximum exercise after rHuEPO therapy must follow those of maximal O₂ flow from muscle capillary to mitochondria. However, different reports examining muscle cell bioenergetics in these patients provide conflicting results (18–22). The primary aim of the present study was the analysis of the relationships between muscle O₂ transport and cellular bioenergetics, assessed by ³¹P-nuclear magnetic resonance spectroscopy (³¹P-MRS), before and after erythropoietin therapy. Post-rHuEPO data were compared with those obtained in healthy sedentary subjects. Because we were specifically interested in the analysis of muscle O₂ transport and ³¹P-MRS data at maximum $\dot{V}O_2$, the exercise protocol was set to explore exercise performance above 70% whole-body $\dot{V}O_2$ peak.

Methods

Patients. Eight anemic subjects (age 27±7.3 [mean±SD] yr), seven men and one woman, with chronic renal failure undergoing regular hemodialysis for an average of 12±11 mo, were enrolled in the proto-

col and studied pre- and post-rHuEPO therapy. Anthropometric, lung function data, adequacy of hemodialysis, and hemoglobin concentration [Hb] before and after rHuEPO therapy using standard dosage (82±12 UI × kg⁻¹ × wk⁻¹) are listed in Table I. Eight additional healthy sedentary men, selected on the basis of no previous history of regular or even occasional physical exercise above that required for the average daily activities, were also studied once using an identical protocol and were used as a control group (Table I). All were informed of any risks and discomfort associated with the experiment, and informed consent was obtained in accordance with the Committee on Investigations Involving Human Subjects at the Hospital Clínic, Universitat de Barcelona. None of these subjects were the same individuals examined in the accompanying paper (10).


Exercise protocol. Exercise tests were performed using an ergometer made of nonmagnetic materials conceived to fit into a standard whole body magnet. The system, described in detail in reference 24, allowed flexion and extension of both legs by alternatively pressing two foot pedals connected to a controlled flow resistance hydraulic system while the subject lay supine on the ergometer table. A piezoelectric force transducer (9251A; Kistler Instruments AG, Winterthur, Switzerland) placed inside one of the pedals was used to determine maximum force of contraction (maximal voluntary contraction, MVC) of the leg and to provide an “on line” control of both strength and rate of pedalling during the exercise test. The exercise protocol, performed at 100 cycles × min⁻¹, consisted of a maximum of 5 periods of 2 min exercise at workloads of 20, 25, 30, 35, and 40% of MVC interspersed by resting periods of 2.5 min. Each subject’s MVC was calculated as the mean of three measurements. It should be pointed out that the above mentioned percentages of MVC greatly exceed the corresponding values of $\dot{V}O_2$. As reported below, the work load at 20% MVC corresponded to a whole-body $\dot{V}O_2$ value above 70% of maximum. In each exercise test, the peak workload was defined by the inability to maintain for 30 s the rate of pedalling due to exhaustion.

Study design. In each study, the patient exercised breathing room air (F_IO₂ = 0.21) on two different days, less than 1 wk apart, using the same ergometer and performing the same exercise protocol. On the

Table I. Anthropometric Data, Lung Function, Adequacy of Dialysis, and Changes in Hemoglobin Concentration

Subject	Age	Height	Weight	FEV ₁	FEV ₁ /FVC	PaO ₂	Kt/V	PCR	HD	Dialyzer	[Hb]	[Hb]	Δ[Hb]	
	yr	cm	kg	liters	%pred	mmHg	urea	g·k ⁻¹ ·day	h·wk ⁻¹		pre-rHuEPO	post-rHuEPO	g·dl ⁻¹	
CRF patients (n = 8)														
VVM	20	173	57	4.3	(98)	85	101	1.0	1.1	12	C 1.4	8.5	11.8	3.3
JCP	41	170	61	3.7	(99)	84	101	1.1	1.0	10.5	CA 1.6	7.8	10.7	2.9
ESG	25	160	54	3.7	(99)	83	112	1.3	1.2	12	C 1.4	7.3	11.2	3.9
JPF	21	163	50	3.9	(99)	84	101	1.1	1.0	10.5	C 1.2	7.6	11.8	4.2
IEC	34	159	59	3.5	(102)	76	99	1.2	1.1	12	CA 1.4	6.6	12.1	5.5
DGR	30	173	62	3.8	(92)	77	97	1.1	1.1	12	C 1.6	8.5	13.3	4.8
ARC	22	178	71	5.4	(95)	85	95	1.3	1.2	12	C 1.8	7.3	11.3	4.0
EMC	24	170	66	3.7	(89)	87	91	1.3	1.2	12	C 1.6	8.6	11.1	2.5
Mean	27	168	60	4.0	(96)	83	100	1.2	1.1	11.6		7.8	11.7	3.9
SD	7	6	7	0.6	4	4	6	0.1	0.1	0.7		1.0	0.8	0.9
Control group (n = 8)														
Mean	26	174	71	4.3	(101)	82	102					14.1		
SD	3	5	6	0.7	4	3	1					1.0		

Results expressed as mean±SD; CRF patients, eight patients with chronic renal failure; Control group, eight healthy sedentary subjects; FEV₁, forced expiratory volume in the first s in liters, and as percentage of predicted value within parentheses (23); FEV₁/FVC, FEV₁ to forced vital capacity ratio; PaO₂, PO₂ in arterial blood; Kt/V (urea), indicates the decrease of BUN during each dialysis treatment, dimensionless; PCR, protein catabolic rate expressed in g·k⁻¹·d; HD, duration of dialysis in h·wk⁻¹ (three times a wk); Dialyzer, type of membrane of the dialyzer and surface expressed in square meters: C 1.4, Cuprophane 1.4 m², CA 1.6, Cellulose Acetate 1.6 m²; [Hb] pre-rHuEPO and [Hb] post-rHuEPO, hemoglobin concentration in the pre-rHuEPO and post-rHuEPO studies expressed in g·dl⁻¹, respectively; Δ[Hb], increase in [Hb] after rHuEPO therapy.



first day, rest and exercise ^{31}P -MRS were obtained without catheters. On the second day, the subject followed the identical exercise protocol (in time and load) outside the magnet with three catheters in place to obtain O_2 transport data. One of the catheters was placed in the radial artery of the contralateral side to the arterio-venous fistula to measure PO_2 , PCO_2 , pH, SaO_2 , lactate, and $[\text{Hb}]$ in arterial blood. In the femoral venous vein of the left leg, a 7-F catheter was advanced 7 cm into the vessel with the tip distally oriented (16), and a 2.5-F thermistor was advanced 5 cm proximally. Measurements of femoral venous blood flow by short term steady state thermodilution principle and measurements of the above variables in arterial and femoral venous blood were obtained. All patients were strongly encouraged to maintain the same level of daily physical activity between the pre- and post-rHuEPO studies despite any improvement in their quality of life. The time elapsed between pre- and post-rHuEPO studies was 4.2 ± 1 mo.

^{31}P -MRS measurements. Studies were carried out using a 1.5 T General Electric Signa Advantage System (General Electric, Milwaukee, WI) (160×52 cm bore) operating at a frequency of 63.65 and 25.86 MHz for the hydrogen-1 and the phosphorus-31 nucleus, respectively, connected to a Spectroscopy Analysis Workstation SUN 3/470 (Sun Microsystems Inc., Mountain View, CA). Subjects were placed in the magnet in a supine position, head first, and the elliptical distributed capacitance surface coil (14.5×6.5 cm), pretuned at the phosphorus resonant frequency, was positioned and fixed over the vastus medialis muscle of the left leg. Then, the MVC was determined and the position of the surface coil was checked with spin-echo T1-weighted images as described in detail in reference 24. Phosphorus-31

Figure 1. Plots of $[\text{PCr}]$ and $[\text{Pi}]$ (y-axis) over time, expressed in s (x-axis). Filled squares correspond to serial measurements carried out immediately after an exercise step in a representative patient. Continuous lines represent the monoexponential fitting to measured data points used to estimate $[\text{PCr}]$ and $[\text{Pi}]$ extrapolated at time zero after exercise ($[\text{PCr}]_0$ and $[\text{Pi}]_0$, respectively). See Methods for additional explanations.




Figure 2. Plots of the ^{31}P -MRS variables (y-axis) measured during sub-maximal and peak exercise as a function of one-leg O_2 uptake expressed in $\text{ml} \times \text{kg}^{-1} \times \text{min}^{-1}$ (x-axis). $[\text{PCr}]/[\text{Pi}]$, phosphocreatine to inorganic phosphate ratio at time 0 after each workload; $\%[\text{PCr}]$ consumption, percentage of $[\text{PCr}]$ consumed during each workload compared to the measurements done immediately before commencing the exercise at each workload; half-time of $[\text{PCr}]$ recovery during the resting period after each work load, expressed in s; and, intracellular pH, intracellular pH at 8 s after each exercise period. In each panel, the three initial workloads correspond to measurements done at 20, 25, and 30% of MVC, which were carried out in all the subjects studied. The highest workload corresponds to the measurements done at peak exercise. Results are expressed as mean \pm SEM.




Figure 3. [PCr]/[Pi] ratio, % [PCr] consumption, and half-time of [PCr] recovery, expressed in s, (y-axis) as a function of intracellular pH (x-axis). Results are expressed as mean \pm SEM. See text for additional explanations.

spectra were obtained using 180° pulses as measured at the center of the coil. A total of 1,024 data points were collected over a spectral width of 2,500 Hz.

Measurements at rest. Four dummy scans plus 128 transients were accumulated for each spectrum with a recycling time of 2 s. Before Fourier transform, a zero filling to 2,048 data points and apodization by exponential multiplication of 3 Hz were applied to the free induction decay. Spectra were manually phased and baseline was corrected using a c-spline function.

Measurements during exercise. After four initial dummy scans, spectra of 8 transients with a repetition time of 2 s (resolution time of 16 s) were continuously recorded being the first spectrum obtained at rest before starting the exercise. Before Fourier transform, manual phase and baseline correction, a zero filling to 2,048 data points and apodization by exponential multiplication of 5 Hz were applied to the

free induction decay. For all spectra, the area under each resonance and its chemical shift were obtained after adjusting to pure Lorentzian lines by the Marquardt-Levenberg fitting routine. The spectra collected in the resting period between successive workloads were used for analysis, but those collected during the 2 min exercise could not be analyzed because of the movements of the legs. The collection of a new set of spectra was initiated just after the end of the exercise at each workload. The phosphocreatine ([PCr]) and the inorganic phosphate ([Pi]) concentrations were therefore extrapolated to time 0 after cessation of exercise at each workload ($[PCr]_0$ and $[Pi]_0$, respectively) by fitting the resonance area values to monoexponential functions with the Enzfitter version 1.03 software package (Elsevier-Biosoft, Cambridge, UK) (Fig. 1). The $[PCr]_0$ and $[Pi]_0$ were used to calculate the [PCr]/[Pi] ratio, the % [PCr] consumption at each workload (% [PCr] consumption), and the individual half-time recovery of phosphocreatine after each exercise step. The intracellular pH (pHi) was calculated using the formula: $pHi = 6.75 + \log [(d - 3.27)/(5.69 - d)]$, where d is the chemical shift distance in ppm between the Pi and the PCr resonances (25). Both the pHi calculated from the first spectrum (8 s) after cessation of exercise and that corresponding to the nadir during the recovery period were analyzed.

O₂ transport measurements. Subject preparation, safety precautions, and technical aspects of the measurement of femoral venous blood gases and blood flow have been described in detail previously (10, 16, 26). On-line calculations of whole-body O₂ uptake ($\dot{V}O_2$), CO₂ output, minute ventilation, respiratory exchange ratio, heart rate, and respiratory rate were averaged sequentially over 15 s intervals and then displayed on a screen monitor to observe the progress of the tests. In each test, measurements were made at rest and during the second min at each workload. In each instance the following measurements were made: (a) PO₂, PCO₂, pH (IL model 1302, pH/Blood gas analyzer and tonometer model 237; Instrumentation Laboratories, Milan, Italy), oxyhemoglobin saturation, hemoglobin concentration ([Hb]) (IL 482 co-oximeter), and blood lactate concentrations (YSI 23L blood lactate analyzer; Yellow Springs Instruments, Yellow Springs, OH) from simultaneous arterial and femoral venous blood samples; and (b) femoral venous blood flow (\dot{Q}_{leg}) by thermodilution and arterial pressure. Calculations of the variables have been previously reported in detail in reference 10.

Data analysis. Results are expressed as mean \pm SD. After rHuEPO, changes in \dot{Q}_{leg} were compared using an analysis of covariance after demonstrating existence of a linear relationship between \dot{Q}_{leg} and whole-body $\dot{V}O_2$ (as work rate was increased) with no variations in the slope from pre- to post-rHuEPO. Comparisons between pre- and post-rHuEPO studies were done using Student paired t test, and those between post-rHuEPO and the control group of healthy sedentary subjects were carried out using Student unpaired t test. Unless otherwise stated, comparisons of submaximal exercise were done using pooled data. Statistical significance was set at $P \leq 0.05$.

Results

Anthropometric data, age, lung function, and changes in [Hb] in the eight CRF patients and the corresponding data from the eight controls are indicated in Table I. After rHuEPO, [Hb] increased by $3.9 \pm 0.9 \text{ g} \times \text{dl}^{-1}$ (50%), from 7.8 ± 1.0 to $11.7 \pm 0.8 \text{ g} \times \text{dl}^{-1}$ ($P = 0.0001$).

Effects of rHuEPO therapy on cellular bioenergetics. Erythropoietin therapy did not affect the phosphocreatine to inorganic phosphate ratio ([PCr]/[Pi]) either at rest (8.9 ± 1.2 vs. 8.8 ± 1.2 , pre- and post-rHuEPO, respectively) or, at a given $\dot{V}O_2$ leg, during exercise (Fig. 2). Likewise, during submaximal and peak exercise, no significant changes in (a) [PCr] consumption expressed as percentage of the [PCr] measured immediately before each work load (% [PCr] consumption); (b) intracellular pH (pHi); nor in (c) half-time of [PCr] recovery




Figure 4. Left: Femoral venous pH (y-axis) as a function of one-leg O₂ uptake expressed in ml × kg × min⁻¹ (x-axis). Right: Relationships between femoral venous pH (y-axis) and intracellular pH (x-axis) in the three groups. See text for additional explanations.

Table II. O₂ Transport Variables during Submaximal and Peak Exercise (n = 8)

		Rest	20% MVC	25% MVC	30% MVC	Peak exercise	P pre-post	P post-con
PfvO ₂ mmHg	Pre-rHuEPO	32.2±8.8	22.2±2.0	22.1±3.3	20.1±3.1	20.2±3.0	0.01	NS
	Post-rHuEPO	44.3±13.9	26.2±6.2	25.5±4.2	24.7±4.6	25.9±5.6		
	Control	43.8±11.9	24.3±4.2	23.0±2.7	21.6±2.1	21.8±3.1		
PfvCO ₂ mmHg	Pre-rHuEPO	39.0±3.3	59.7±6.6	57.3±5.3	53.7±7.3	53.3±7.2	NS	0.02
	Post-rHuEPO	36.9±4.0	58.1±6.8	54.3±4.3	52.9±8.0	53.2±6.9		
	Control	40.2±3.4	64.1±10.3	63.7±7.3	62.3±5.7	62.0±6.9		
pH _{fv}	Pre-rHuEPO	7.39±0.02	7.20±0.05	7.18±0.06	7.17±0.05	7.15±0.05	NS	NS
	Post-rHuEPO	7.38±0.03	7.21±0.04	7.19±0.04	7.18±0.04	7.16±0.04		
	Control	7.42±0.04	7.24±0.08	7.20±0.07	7.19±0.06	7.15±0.06		
CaO ₂ m·100ml ⁻¹	Pre-rHuEPO	10.7±0.9	10.8±0.9	10.8±0.8	10.9±0.9	10.9±0.8	0.001	0.001
	Post-rHuEPO	15.7±1.0	15.8±0.9	16.1±1.1	16.3±1.1	16.3±1.2		
	Control	19.2±1.4	19.6±1.5	19.7±1.9	19.7±2.0	19.9±1.8		
CfvO ₂ m·100ml ⁻¹	Pre-rHuEPO	6.9±0.5	3.7±0.3	3.3±0.2	2.9±0.1	2.9±0.1	0.001	0.001
	Post-rHuEPO	12.3±0.9	5.8±0.4	5.5±0.3	5.3±1.0	5.2±0.4		
	Control	15.7±1.0	6.6±0.7	5.8±0.5	5.1±0.4	4.8±0.4		
Q _{leg} liter.min ⁻¹	Pre-rHuEPO	—	3.4±0.6	3.9±0.8	4.9±1.5	4.9±1.5	0.04	NS
	Post-rHuEPO	—	3.0±0.9	3.3±0.6	3.6±0.8	3.9±1.0		
	Control	—	3.0±0.4	3.8±0.6	4.4±0.5	4.7±0.8		
Q _{O₂leg} liter.min ⁻¹	Pre-rHuEPO	—	0.37±0.09	0.43±0.10	0.52±0.20	0.54±0.19	NS	0.001
	Post-rHuEPO	—	0.47±0.13	0.53±0.08	0.57±0.10	0.63±0.13		
	Control	—	0.59±0.10	0.75±0.15	0.86±0.16	0.94±0.16		
O ₂ ER %	Pre-rHuEPO	35±14.8	66±7.6	69±5.3	73±4.1	73±4.0	0.03	0.05
	Post-rHuEPO	22±18.2	63±6.9	65±6.9	67±7.9	68±8.2		
	Control	18±14.5	67±8.5	70±7.1	74±5.3	76±6.1		
V _{O₂leg} liter.min ⁻¹	Pre-rHuEPO	—	0.25±0.07	0.29±0.07	0.40±0.16	0.40±0.15	NS	0.001
	Post-rHuEPO	—	0.29±0.07	0.34±0.05	0.38±0.05	0.43±0.09		
	Control	—	0.39±0.07	0.53±0.12	0.64±0.11	0.71±0.13		

Results expressed as mean±SD; 20, 25 and 30% MVC, correspond to the submaximal workloads carried out in all the subjects (actual values of each of these workloads expressed in watts are indicated in Table III); peak exercise, measurements obtained at exhaustion; Pre-rHuEPO, Post-rHuEPO, and Control, results before rHuEPO therapy, post-rHuEPOtherapy, and from the sedentary control subjects respectively; PfvO₂, PfvCO₂, and pH_{fv}, femoral venous PO₂, PCO₂, and pH, respectively; CaO₂, CfvO₂, O₂ content in arterial and femoral venous blood, respectively; Q_{leg}, femoral venous blood flow; Q_{O₂leg}, one-leg O₂ delivery; O₂ ER, muscle O₂ extraction as a percentage; V_{O₂leg}, one leg O₂ uptake; pre-post, probability of the comparisons between pre and post-rHuEPO measurements at peak exercise (paired analysis); post-con, probability of the comparisons between post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).

after each exercise step, expressed in seconds, were observed after rHuEPO.

Comparison of ^{31}P -MRS between post-rHuEPO and controls. The [PCr]/[Pi] ratio at rest was significantly higher in controls than in the post-rHuEPO group (10.9 ± 1.5 vs. 8.8 ± 1.2 , respectively) ($P = 0.01$). As shown in Fig. 2, at a given $\dot{V}\text{O}_2\text{leg}$, the energetic status of the muscle cells as reflected by [PCr]/[Pi], % [PCr] consumption and half-time of [PCr] recovery and the intracellular pH was significantly higher in controls. For example, at a $\dot{V}\text{O}_2\text{leg}$ of $\sim 6.2 \text{ ml} \times \text{kg}^{-1} \times \text{min}^{-1}$, the ^{31}P -MRS results were (a) [PCr]/[Pi] ratio, 0.60 ± 0.33 vs. 0.26 ± 0.13 , control and post-rHuEPO group, respectively) ($P = 0.023$); (b) % [PCr] consumption, 68 ± 15.5 vs. $82 \pm 9.7\%$ ($P = 0.067$); (c) half-time of [PCr] recovery, 9 ± 6.8 vs. 30 ± 18.7 s ($P = 0.013$); (d) pHi calculated from the first spectrum (8 s) after cessation of exercise, 6.77 ± 0.15 vs. 6.55 ± 0.23 ($P = 0.05$); and (e) pHi corresponding to the nadir during the recovery period, 6.68 ± 0.16 vs. 6.37 ± 0.21 , respectively ($P = 0.012$). However, the differences between post-rHuEPO and control group in [PCr]/[Pi] ratio and % [PCr] consumption during exercise and in half-time of [PCr] recovery during the interspersed resting periods disappeared when these variables were expressed as a function of pHi. Identical results were obtained either using pHi calculated from the first spectrum (8 s) after cessation of exercise (Fig. 3) or that corresponding to the nadir during the recovery period.

Relationships between intracellular pH and femoral venous pH. No differences in femoral venous pH (pH_{fv}), at a given $\dot{V}\text{O}_2\text{leg}$, were observed between pre- and post-rHuEPO studies. As depicted in Fig. 4 (right), intracellular and femoral venous pH track each other in all three groups.

Effects of rHuEPO therapy on muscle O_2 transport. Arterial O_2 content (CaO_2) increased by 50% ($P < 0.001$), parallel to the rise observed in [Hb] (Table II). However, femoral venous blood flow ($\dot{Q}\text{leg}$) was consistently lower ($\sim 20\%$) at each workload after rHuEPO ($P < 0.04$) (Fig. 5). The reduction in $\dot{Q}\text{leg}$ largely offset the effect of the increase in CaO_2 on O_2 delivery ($\dot{Q}\text{O}_2\text{leg}$). At peak exercise, $\dot{Q}\text{O}_2\text{leg}$ did not change significantly after rHuEPO, the mean value increasing by 17%.

We confirmed existence of a low muscle O_2 conductance (DO_2) in CRF patients as previously seen (10), but no increase in DO_2 after rHuEPO was found (10.9 ± 4.2 and $10.9 \pm 2.6 \text{ ml} \times \text{mmHg}^{-1} \times \text{min}^{-1}$, pre- and post-rHuEPO, respectively). As indicated in Table II, one-leg O_2 extraction ratio (O_2ER) decreased after rHuEPO therapy at each workload. At maximum exercise, O_2ER fell from 73 ± 4.0 to $68 \pm 8.2\%$ ($P = 0.03$). Consequently, the 17% increase in $\dot{Q}\text{O}_2\text{leg}$ was counterbalanced by the 7% drop in O_2ER such that both $\dot{V}\text{O}_2\text{leg}$ (Table II) and whole-body $\dot{V}\text{O}_2$ (Table III) did not change significantly (only +8 and +6%, respectively) after rHuEPO therapy.

Comparison of muscle O_2 transport at peak exercise between post-rHuEPO and controls. Muscle O_2 transport variables at peak exercise expressed as percent of the values obtained in the control subjects are shown in Fig. 6 (mean \pm SEM). Both [Hb] and CaO_2 in the CRF patients post-rHuEPO were $\sim 18\%$ lower than the corresponding values in the control group, whereas peak $\dot{Q}\text{leg}$ was similar (65 ± 1.1 vs. $67 \pm 1.2 \text{ ml} \times \text{kg}^{-1} \times \text{min}^{-1}$, post-rHuEPO and controls respectively). Consequently, $\dot{Q}\text{O}_2\text{leg}$ was $\sim 20\%$ lower in CRF patients post-rHuEPO. As expected from the low muscle O_2 conductance in CRF patients, O_2ER after rHuEPO was also lower




Figure 5. Relationships between femoral venous blood flow ($\dot{Q}\text{leg}$), expressed in $\text{ml} \times \text{kg}^{-1} \times \text{min}^{-1}$ (y-axis) and whole-body O_2 uptake, expressed in $\text{ml} \times \text{kg}^{-1} \times \text{min}^{-1}$ (x-axis). At any given $\dot{V}\text{O}_2$, $\dot{Q}\text{leg}$ significantly decreased after rHuEPO. No differences were detected between the post-rHuEPO and controls. Results are expressed as mean \pm SEM.

than in controls (68 ± 8.2 and $76 \pm 6.1\%$, respectively) ($P = 0.05$). The combined effects of $\dot{Q}\text{O}_2\text{leg}$ and O_2ER on O_2 uptake explain how peak $\dot{V}\text{O}_2\text{leg}$ in CRF patients post-rHuEPO was 28% lower than that observed in controls (7.2 ± 1.4 and $10.0 \pm 1.6 \text{ ml} \times \text{kg}^{-1} \times \text{min}^{-1}$, respectively) ($P = 0.002$).

Discussion

Main findings. The present study confirms our previous results (10) suggesting that the limited increase of maximum O_2 uptake ($\dot{V}\text{O}_2\text{max}$) in anemic patients with chronic renal failure (CRF) after increasing the [Hb] up to almost normal levels with rHuEPO therapy can be essentially explained by: (a) hemodynamic changes (reduction of leg blood flow) after rHuEPO; and (b) abnormal muscle O_2 conductance from microcirculation to mitochondria (10). The structural basis for the reduced muscle O_2 conductance in CRF patients is likely to be a poor muscle microcirculatory network and capillary-myofiber dissociation (11–13) due to uremic myopathy. Two main findings come from the present investigation.

First, muscle cell bioenergetics as characterized by ^{31}P -MRS signals reflecting [PCr], [Pi], and derived indices (at rest, during exercise, and throughout the recovery period after each exercise step) did not show significant changes after rHuEPO therapy. We suggest that in the face of O_2 supply limitation of $\dot{V}\text{O}_2\text{max}$ (10), the lack of significant changes in convective O_2 delivery ($\dot{Q}\text{O}_2\text{leg}$) can explain lack of increase in O_2 flow to mitochondria, and consequently how ^{31}P -MRS data and $\dot{V}\text{O}_2\text{max}$ both did not change with rHuEPO in the present investigation. Since O_2 supply dependency of $\dot{V}\text{O}_2\text{max}$ in CRF patients was demonstrated in the companion study (10); limited mitochondrial oxidative capacity does not appear to explain the lack of increase in $\dot{V}\text{O}_2\text{max}$ after rHuEPO therapy, if

Table III. Whole-body Variables during Submaximal and Peak Exercise (n = 8)

		Rest	20% MVC	25% MVC	30% MVC	Peak exercise	P pre-post	P post-con
Watts	Pre-rHuEPO	0	33±7	42±10	53±12	57±16	NS	NS
	Post-rHuEPO	0	33±7	42±10	53±12	55±17		
	Control	0	36±6	47±11	58±16	65±17		
$\dot{V}O_2$ liters·min ⁻¹	Pre-rHuEPO	0.25±0.05	1.26±0.25	1.44±0.34	1.64±0.42	1.67±0.54	NS	NS
	Post-rHuEPO	0.28±0.07	1.39±0.40	1.52±0.45	1.65±0.33	1.77±0.48		
	Control	0.27±0.06	1.40±0.36	1.70±0.23	1.90±0.22	2.03±0.30		
$\dot{V}O_2$ ml·min ⁻¹ ·kg ⁻¹	Pre-rHuEPO	4.1±1.0	20.9±4.2	24.0±6.0	26.4±6.2	27.6±8.0	NS	NS
	Post-rHuEPO	4.8±1.2	23.5±6.7	25.7±7.7	27.9±5.7	29.8±6.9		
	Control	3.8±0.7	19.7±5.0	24.0±3.7	26.4±3.5	28.7±4.6		
HR min ⁻¹	Pre-rHuEPO	84±14	136±16	151±20	163±13	164±10	NS	NS
	Post-rHuEPO	81±13	134±20	152±22	163±11	168±10		
	Control	76±12	129±24	155±23	164±20	171±8		
[Lact] _a mM	Pre-rHuEPO	0.6±0.2	3.0±0.7	5.7±1.5	7.8±2.1	8.6±2.7	0.01	0.04
	Post-rHuEPO	0.5±0.2	2.6±1.4	4.2±1.9	5.7±2.3	6.0±1.9		
	Control	0.6±0.2	2.7±0.6	5.2±1.7	6.7±1.8	7.8±1.1		

Results expressed as mean±SD; 20, 25 and 30% MVC, correspond to the submaximal workloads carried out in all the subjects (actual values of each of these workloads expressed in watts are indicated in this table); peak exercise, measurements obtained at exhaustion; Pre-rHuEPO, Post-rHuEPO, and Control, results before rHuEPO therapy, post-rHuEPO therapy, and from the sedentary control subjects respectively; Watts, workload at each exercise step expressed in watts; $\dot{V}O_2$, O₂ uptake; HR, heart rate; [Lact]_a, lactate concentration in arterial blood expressed in mM; pre-post, probability of the comparisons between pre and post-rHuEPO measurements at peak exercise (paired analysis); post-con, probability of the comparisons between post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).

we assume that supply dependency was also the case in the present patient group.

The second major finding was that the ³¹P-MRS results (Fig. 2) depict a lower muscle cell bioenergetic status and a lower intracellular pH (pHi), at a given $\dot{V}O_{2leg}$, in CRF pa-




Figure 6. Results of muscle O₂ transport variables expressed as percent of the values obtained in the sedentary control subjects. \dot{Q}_{leg} , $\dot{Q}O_{2leg}$, and $\dot{V}O_{2leg}$ have been corrected by body weight. Values are expressed as mean±SEM. *P < 0.05 between pre- and post-rHuEPO (Student's paired t-test); ‡P < 0.05 between post-rHuEPO and controls (Student's unpaired t-test).

tients post-rHuEPO compared to controls. The longer half-time of [PCr] recovery in CRF patients would suggest reduced mitochondrial function, but because of the complexity of the processes regulating oxidative phosphorylation in the mammalian cell (26), the identification of the precise mechanism(s) responsible for the observed differences between CRF patients and controls is beyond the scope of the present study. However, it should be pointed out that the differences in [PCr] breakdown and in half-time of [PCr] recovery between CRF patients post-rHuEPO and control disappeared when these variables ([PCr]/[Pi] ratio, % [PCr] consumption and half-time [PCr] recovery) are expressed as a function of pHi (Fig. 3). Increase in half-time of [PCr] recovery related with low pHi values, but not due to changes in muscle O₂ supply, has been reported by McCully et al. (28). Low pHi values increase the half-time of [PCr] recovery as a result of the effect of [H⁺] on the creatine kinase reaction such that PCr levels no longer strictly depend on changes in ADP concentration. Low pHi can also inhibit adenosinetriphosphatase rates and lower oxidative capacity (29). The behavior of these energetic indices as a function of pHi suggests that the ³¹P-MRS abnormalities may be primarily due to [H⁺]-related cytosolic effects on the regulation of the processes involved in [PCr] breakdown and resynthesis rather than to a primary disturbance of the mitochondrial oxidative capacity (30, 31). The marked differences in pHi between patients and controls, at a given $\dot{V}O_{2leg}$, may be in larger part explained by different lactate levels (Table III), although without intracellular lactate concentrations this is somewhat speculative. The slightly lower [Hb] (Table I) observed in post-rHuEPO patients compared with controls does not perturb the interpretation of the differences in cellular bioenergetics.

Structural and histochemical findings in skeletal muscle biopsies obtained in CRF patients (11–13) indicate poor capillary network and capillary-myofiber dissociation as the foremost characteristic findings, but also myopathic changes that could decrease oxygen-dependent metabolism. Abnormal oxidative capacity is claimed to exist in CRF patients by some authors (19). Diesel et al. (13) also argued for a reduced muscle oxidative capacity in CRF patients but these authors used an inadequate control group consisting of trained athletes rather than sedentary subjects. In contrast, Moore et al. (18) suggest preserved intrinsic oxidative mitochondrial capacity in dialysis patients as compared to transplant recipients and healthy subjects, based on their similar post-exercise recovery of [PCr]/[Pi] ratio and pHi to baseline energy status. The present study provides two new insights compared to the work done by Moore et al. (18). First, we examine the effects of a marked increase in [Hb] after rHuEPO therapy (by 50%) on muscle bioenergetics. Second, in the present study interpretation of energetic status of the cell (both in the comparison between pre- and post-rHuEPO therapy and in the analysis of the differences between CRF patients post-rHuEPO and healthy sedentary controls) was done, for the first time, using actual muscle O₂ transport and O₂ uptake data obtained while the subject was performing identical exercise protocol and using the same ergometer. Hence, unnecessary assumptions and uncertainties such as the nature of static and dynamic hand-grip exercise (18) can be avoided.

Differences in O₂ transport response to rHuEPO between the present study and reference 10. Despite the marked increase in [Hb] in both investigations (50 and 69%, present study and reference 10, respectively), the weak O₂ transport response after rHuEPO in the present protocol was indeed more evident. The fall in Q_{leg} after rHuEPO was slightly greater than that seen in reference 10, and at variance with the previous study, muscle oxygen extraction ratio (O₂ER) significantly decreased after rHuEPO. These two phenomena can account for the lack of change in one-leg O₂ uptake at peak exercise after rHuEPO. A similar lack of response to the rHuEPO therapy was also found in whole-body O₂ uptake at peak exercise which, as indicated in Methods, is a fully independent measurement from one-leg $\dot{V}O_2$ ($\dot{V}O_{2,leg}$). Since all measurements were done while subjects were breathing room air only, DO₂ in this study is analyzed subject to the assumption of O₂ supply dependency which was demonstrated in reference 10. The technical requirements to estimate muscle O₂ conductance have been analyzed in detail elsewhere (10, 16, 32–35). However, it is of note that post-rHuEPO DO₂ in these patients (10.9±1.6 ml × mmHg⁻¹ × min⁻¹) was ~ 60% of that obtained in controls (18.2±3.5 ml × mmHg⁻¹ × min⁻¹). As suggested by Piiper et al. (14) and shown elsewhere (10, 16), the observed reduction of the O₂ER after rHuEPO from 73±4.0 to 68±8.2% ($P < 0.03$) necessarily requires a decrease in diffusional to perfusional conductance ratio (DO₂/β × Q_{leg}) after rHuEPO. The term β corresponds to the slope of the O₂ dissociation curve and is the ratio of the arterial to femoral venous O₂ content difference and the arterial to femoral venous PO₂ difference [$\beta = (C_aO_2 - C_vO_2)/(P_aO_2 - P_vO_2)$].

The above described differences in muscle O₂ transport between these two investigations (present study and 10), as well as the lack of change in DO₂ after rHuEPO in the present study, can be ascribed to the combined effects of two factors: (a) the smaller increase in [Hb] after rHuEPO in this study

compared to reference 10 (50 vs. 69%, respectively); and (b) the larger reduction in peak Q_{leg} after rHuEPO in the present investigation (by -20%, from 82 to 65 ml × kg⁻¹ × min⁻¹) compared to that observed in reference 10 (by -13%, from 84 to 73 ml × kg⁻¹ × min⁻¹). The two groups of CRF patients showed a similar exercise performance (relationships between $\dot{V}O_2$ and work rate and peak $\dot{V}O_2$), evaluated using a regular cycloergometer (post-rHuEPO whole-body $\dot{V}O_{2,max}$, 30.6±6.6 and 33.1±4.7 ml × kg⁻¹ × min⁻¹, present study and reference 10, respectively). The present study and reference 10 were performed at the same time using identical inclusion criteria.

³¹P-MRS data at rest. Differences of resting [PCr]/[Pi] ratios have been reported among normal sedentary subjects, sprinters, and long-distance runners (36), likely reflecting different bioenergetic status associated with differences in muscle fiber-type composition. However, a low [PCr]/[Pi] ratio at rest is a characteristic feature of several different metabolic myopathies (37, 38). In the present study, pre-rHuEPO results were below ($P = 0.01$) those seen in the control group with no significant changes after rHuEPO, indicating a lower muscle energetic status in CRF patients (pre- and post-rHuEPO). We suggest this is probably due to uremic myopathy, rather than related to an abnormal O₂ supply to mitochondria which, at rest, can be assumed largely above cellular O₂ demand. Lower [PCr]/[Pi] ratios in CRF patients compared to their controls ($P < 0.01$) have also been reported by Táborsky et al. (19). In contrast, Moore et al. (18) and Durozard et al. (21) have described a normal resting muscle bioenergetic status in CRF patients. It is of note that Park et al. (20) reported a low [PCr]/[Pi] ratio in CRF patients pre-rHuEPO followed by an increase after rHuEPO therapy, from 6.1±1.1 to 8.7±2.1, which has not been confirmed in the present study. Discrepancies among authors can likely be ascribed to technical factors and differences in the muscle groups explored.

Exercise protocol. We focused the study on the analysis of the relationships between muscle O₂ transport and cellular bioenergetics at maximum exercise. Consequently, the exercise protocol was specifically designed to examine the performance above 70% whole-body $\dot{V}O_{2,peak}$. Recall that the percentages of maximal voluntary contraction (%MVC), reported in Tables II and III, greatly exceed the corresponding percentages of whole-body $\dot{V}O_{2,peak}$. The marked changes in pHi throughout exercise observed in all the groups (Fig. 2, bottom right) might constrain the analysis of changes in [PCr]/[Pi] ratio, % [PCr] consumption, and half-time of [PCr] recovery as markers of mitochondrial oxidative capacity. The latter is often explored using submaximal exercise protocols that provoke negligible changes in pHi. To cope with this potential limitation in the interpretation of the results, the ³¹P-MRS data were also expressed as a function of pHi, as indicated in Fig. 3 and discussed below. An interesting finding of the present study is the strong correlation between femoral venous pH and pHi in the three groups (Fig. 4). Moreover, to reach high intensity levels of exercise, the protocol was set at 100 cycles × min⁻¹ which, in turn, precluded the analysis of the spectra during the leg movements. As indicated in Methods, the PCr and Pi data were extrapolated to time 0 after each work load, and the derived variables ([PCr]/[Pi] ratio, % [PCr] consumption and half-time of [PCr] recovery) were obtained from [PCr]_{t0} and [Pi]_{t0}. Both the correlation of the measured data to a mono-exponential function, as shown in Fig. 1, and indeed the consistency of the ³¹P-MRS data during exercise indicate that the

characteristics of the protocol allowed for the analysis of the relationships between O_2 supply and cellular bioenergetics in the setting.

Effects of rHuEPO on muscle cell bioenergetics during exercise. The analysis of submaximal and peak exercise data (Fig. 2) clearly shows that [PCr]/[Pi] ratio and % [PCr] consumption, at a given $\dot{V}O_{2leg}$, did not change after rHuEPO. Intracellular pH and half-time of [PCr] recovery also did not show significant changes. The lack of effects of rHuEPO on the ^{31}P -MRS data, at a given $\dot{V}O_{2leg}$, suggests that either: (a) biochemical pathways (i.e., mitochondrial oxidative capacity) not related to O_2 supply to the cell may determine the bioenergetic status of the muscle cells in these patients; or (b) that rHuEPO, despite the marked increase in [Hb] (by 50%), did not effectively increase maximal O_2 flow to the myocytes. The latter is the most likely explanation for the ^{31}P -MRS data depicted in Fig. 2 as described above. The lack of changes in muscle O_2 transport after rHuEPO are consistent with this notion. Moreover, since O_2 supply dependency of maximum O_2 uptake in CRF patients was demonstrated in the companion study (10), a reduced oxidative capacity appears unlikely to explain the lack of changes in muscle cell bioenergetics after rHuEPO. Thompson et al. (18) have reported ^{31}P -MRS data measured in three CRF patients studied pre- and post-rHuEPO therapy. These authors suggest that both impaired muscle O_2 transport and limited mitochondrial oxidative capacity play a role limiting maximum exercise performance in these patients. However, the lack of a parallel assessment of muscle O_2 transport in their study limits the interpretation of their results.

In summary, the present study confirms that: (a) reduction in muscle blood flow and (b) abnormal intramuscular O_2 transport due to functional and structural derangement of muscle microcirculation provoked by uremic myopathy can explain the poor peak $\dot{V}O_{2leg}$ response after rHuEPO therapy. The lower pHi, at a given $\dot{V}O_{2leg}$, seen in CRF patients compared to controls, may be also partially explained by the low capillarity associated to uremic myopathy. This low pHi seems to account for the lower [PCr]/[Pi] ratio and the longer half-time of [PCr] recovery, at a given $\dot{V}O_{2leg}$, seen in these patients. However, derangement of the cytosolic regulation of oxidative phosphorylation directly provoked by uremic myopathy can not be ruled out.

Acknowledgments

The authors thank Felip Burgos, Conxi Gistau, Teresa Lecha, Maite Simó, and Carmen Argaña (Lung Function Laboratory) for their outstanding technical support; C Santos, M.D. (Uruguay) for her assistance in the studies; and Lluís de Jover, M.D. for his statistical assistance. The Centre d'Alt Rendiment (CAR) de Sant Cugat del Vallés and the Sandoz Sport Research Project allow us to use the ergometer. We are also grateful to the patients, the dialysis centers and the Registre de Malalts Renals de la Generalitat de Catalunya for their enthusiastic collaboration in the study.

Supported by grants FIS 92-0318 and 94-1106 from the Fondo de Investigaciones Sanitarias, Comissionat per Universitats i Recerca de la Generalitat de Catalunya (GRQ 94-9103), and HL-17731 from the National Heart, Lung and Blood Institute. Ramon M. Marrades was a research fellow supported by the Hospital Clínic (1993); Orlando Diaz was a research fellow supported by the Universidad Pontificia Católica de Chile; and Joan R. Masclans was a research fellow supported by the Fondo de Investigaciones Sanitarias (BAE 94/5176).

Peter D. Wagner was a visiting professor (PVI) at the University of Barcelona (1995–1996).

References

1. Eschbach, J.W., J.C. Egrie, M.R. Downing, J.K. Browne, and J.W. Adamson. 1987. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. *N. Engl. J. Med.* 316:73–78.
2. Eschbach, J.W., J. Mladenovic, J.F. Garcia, P.W. Wahl, and J.W. Adamson. 1984. The anemia of chronic renal failure in sheep: response to erythropoietin-rich plasma in vivo. *J. Clin. Invest.* 74:434–441.
3. Eschbach, J.W., and J.W. Adamson. 1988. Recombinant human erythropoietin: implications for nephrology. *Am. J. Kidney Dis.* 11:203–209.
4. Canadian Erythropoietin Study Group. 1990. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. *Br. Med. J.* 300:573–578.
5. Maccougall, I.C., N.P. Lewis, M.J. Saunders, D.L. Cochlin, M.E. Davies, R.D. Hutton, K.A.A. Fox, G.A. Coles, and J.D. Williams. 1990. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. *Lancet.* 335:489–493.
6. Robertson, H.T., N.R. Haley, M. Guthrie, D. Cardenas, J.W. Eschbach, and J.W. Adamson. 1990. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. *Am. J. Kidney Dis.* 15:325–332.
7. Satoh, K., T. Masuda, Y. Ikeda, S.H. Kurokawa, K. Kamata, R. Kikawada, T. Takamoto, and F. Marumo. 1990. Hemodynamic changes in recombinant erythropoietin therapy in hemodialyzed patients. *Hypertension (Dallas).* 15:262–266.
8. Metra, M., G. Cannella, G. La Canna, T. Guaini, M. Sandrini, M. Gaggiotti, E. Movilli, and L. Dei Cas. 1991. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. *Am. J. Cardiol.* 68:1060–1066.
9. Davenport, A. 1993. The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis. *Am. J. Kidney Dis.* 22:685–690.
10. Marrades, R.M., J. Roca, J. Campistol, O. Diaz, J.A. Barberà, J.V. Torregrosa, J.R. Masclans, A. Cobos, R. Rodriguez-Roisin, and P.D. Wagner. 1996. Effects of erythropoietin therapy on muscle O_2 transport in patients with chronic renal failure. *J. Clin. Invest.* 97:2092–2100.
11. Bradley, J.R., J.R. Anderson, D.B. Evans, and A.J. Cowley. 1990. Impaired nutritive skeletal muscle blood flow in patients with chronic renal failure. *Clin. Sci.* 79:239–245.
12. Moore, G.E., B. Parsons, J. Stray-Gundersen, P.L. Painter, K.R. Brinker, and J.H. Mitchell. 1993. Uremic myopathy limits aerobic capacity in hemodialysis patients. *Am. J. Kidney Dis.* 22:277–287.
13. Diesel, W., M. Emms, B.K. Knight, T.D. Noakes, R. van Zyl Smit, R.O.C. Kaschula, and C.C. Sinclair-Smith. 1993. Morphologic features of the myopathy associated with chronic renal failure. *Am. J. Kidney Dis.* 22:677–684.
14. Piiper, J., and P. Scheid. 1981. Model for capillary alveolar equilibration with special reference to O_2 uptake in hypoxia. *Respir. Physiol.* 46:193–208.
15. Wagner, P.D. 1993. Algebraic analysis of the determinants of $\dot{V}O_{2max}$. *Respir. Physiol.* 93:221–237.
16. Roca, J., A.G.N. Agustí, J. Alonso, D.C. Poole, C. Viegas, J.A. Barberà, R. Rodriguez-Roisin, A. Ferrer, and P.D. Wagner. 1992. Effects of training on muscle O_2 transport at $\dot{V}O_{2max}$. *J. Appl. Physiol.* 73:1067–1076.
17. Painter, P., and G.E. Moore. 1994. The impact of recombinant human erythropoietin on exercise capacity in hemodialysis patients. *Adv. Renal Replacement Therapy.* 1(1):55–65.
18. Moore, G.E., L.A. Bertocci, and P.L. Painter. 1993. ^{31}P -magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients. *J. Clin. Invest.* 91:420–424.
19. Thompson, C.H., G.J. Kemp, D.J. Taylor, J.G. Ledingham, G.K. Radda, and B. Rajagopalan. 1993. Effect of chronic uraemia on skeletal muscle metabolism in man. *Nephrol. Dial. Transplant.* 8:218–222.
20. Park, J.S., S.B. Kim, S.K. Park, T.H. Lim, D.K. Lee, and C.D. Hong. 1993. Effect of recombinant human erythropoietin on muscle energy metabolism in patients with end-stage renal disease: a ^{31}P -nuclear magnetic resonance spectroscopic study. *Am. J. Kidney Dis.* 21:612–618.
21. Durozard, D., P. Pimmel, S. Baretto, A. Caillette, M. Labeeuw, G. Baverel, and P. Zech. 1993. ^{31}P -NMR spectroscopy investigation of muscle metabolism in hemodialysis patients. *Kidney Int.* 43:885–892.
22. Táboršky, P., I. Sotorník, J. Kaslikova, O. Schük, M. Hájek, and A. Horská. 1993. ^{31}P -magnetic resonance spectroscopy investigation of skeletal muscle metabolism in uraemic patients. *Nephron.* 65:222–226.
23. Roca, J., J. Sanchis, A. Agustí-Vidal, F. Segarra, D. Navajas, R. Rodriguez-Roisin, P. Casan, and S. Sans. 1986. Spirometric reference values from a mediterranean population. *Bull. Eur. Physiother. Respir.* 22:217–224.
24. Gonzalez de Suso, J.M., G. Bernús, J. Alonso, A. Alay, A. Capdevila, J. Gili, J.A. Prat, and C. Artús. 1993. Development and characterization of an ergometer to study the bioenergetics of the human quadriceps muscle by ^{31}P -NMR spectroscopy inside a standard NMR scanner. *Magn. Reson. Med.* 29:575–581.

25. Taylor, D.J., P.J. Bore, P. Stylen, D.G. Gadian, and G.K. Radda. 1983. Bioenergetics of intact human muscle. A ^{31}P -nuclear magnetic resonance study. *Mol. Biol. Med.* 1:77–94.
26. Agustí, A.G.N., J. Roca, J.A. Barberà, J. Casademont, R. Rodríguez-Roisin, and P.D. Wagner. 1994. Effect of sampling site on femoral venous blood gas values. *J. Appl. Physiol.* 77:2018–2022.
27. Deleted in proof.
28. McCully, K.K., S. Iotti, K. Kendrick, Z. Wang, J.D. Posner, J. Leigh, and B. Chance. 1994. Simultaneous in vivo measurements of HbO₂ saturation and PCr kinetics after exercise in normal humans. *J. Appl. Physiol.* 77:5–10.
29. Kemp, G.J., D.J. Taylor, and G.K. Radda. 1993. Control of phosphocreatine resynthesis during recovery from exercise in human skeletal muscle. *NMR Biomed.* 6:66–72.
30. Kemp, G.J. and G.K. Radda. 1994. Quantitative interpretation of bioenergetic data from ^{31}P and ^1H magnetic resonance spectroscopic studies of skeletal muscle: an analytical review. *Magn. Res. Q.* 10(1):43–63.
31. Iotti, S., R. Lodi, C. Frassinetti, P. Zaniol, and B. Barbiroli. 1993. In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by ^{31}P -MRS. *NMR Biomed.* 6:248–253.
32. Wagner, P.D., J. Roca, M.C. Hogan, D.C. Poole, D.E. Bebout, and P. Haab. 1990. Experimental support for the theory of diffusion limitation of maximum oxygen uptake. In *O₂ Transport to Tissue XII*. J. Piiper, T.K. Goldstick, and M. Meyer, editors. New York, Plenum Press. 825–833.
33. Bohr, C. 1909. Über die spezifische Tätigkeit der Lungen bei der Respiratorischen Gasaufnahme und ihr Verhalten zu der durch die Alveolarwand stattfindenden Gasdiffusion. *Scand. Arch. Physiol.* 22:221–280.
34. Roca, J., M.C. Hogan, D.C. Story, D.E. Bebout, P. Haab, R. Gonzalez, O. Ueno, and P.D. Wagner. 1989. Evidence for tissue diffusion limitation of V_{O₂}max in normal humans. *J. Appl. Physiol.* 67:291–299.
35. Wagner, P.D. 1977. Diffusion and chemical reaction in pulmonary gas exchange. *Physiol. Rev.* 57:257–312.
36. Bernús, G., J.M. Gonzalez de Suso, J. Alonso, P.A. Martin, J.A. Prat, and C. Arús. 1993. ^{31}P -MRS of quadriceps reveals quantitative differences between sprinters and long-distance runners. *Med. Sci. Sports Exerc.* 25:479–484.
37. Bendahan, D., S. Confort-Gouny, G. Kozak, and P.J. Cozzone. 1993. Investigation of metabolic myopathies by ^{31}P -MRS using a standardized rest-exercise-recovery protocol: a survey of 800 explorations. *MAGMA.* 1:91–104.
38. Taylor, D.J., B. Rajagopalan, and G.K. Radda. 1992. Cellular energetics in hypothyroid muscle. *Eur. J. Clin. Invest.* 22:358–365.